AlphaVax, Inc., headquartered in Research Triangle Park, has reported initial positive results from a Phase I clinical trial of a vaccine to treat cytomegalovirus (CMV), a herpes virus that is a major cause of morbidity and mortality in congenitally infected infants, and stem cell and organ transplant recipients.
In initial results, a majority of the subjects developed substantial antibody or T cell responses to all three CMV antigens in the vaccine. The trial involves 40 healthy, 18-40 year old, CMV-negative volunteers and is being conducted by David I. Bernstein, M.D., Director of Infectious Diseases at the Cincinnati Children's Hospital Medical Center in Ohio.
AlphaVax, Inc. is a clinical-stage company that uses a novel alphavirus vector platform technology that is highly flexible and immunogenic. In addition to CMV, important disease targets include influenza, cancer, HSV, RSV, and a number of biodefense vaccine products.